Home
Orphazyme

Orphazyme Market Share Analysis for January 2026

Health > Biotechnology and Pharmaceuticals

Domainorphazyme.com

Year Founded2009

Employees51 - 200

Annual Revenue$2M - $5M

Orphazyme

Orphazyme (including company regionals)

orphazyme.com

See more website traffic and engagement information

Orphazyme Revenue up to January 2026 is 2M - 5M

revenue generated by Orphazyme top domains

Orphazyme top domains revenue over 3 years

Revenue for Orphazyme top domains

orphazyme.com2M - 5M

See more with Sales Intelligence

Total visits to Orphazyme's top domains

Understand Orphazyme market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

orphazyme.com--

See more with Sales Intelligence

Avg. visit duration in Orphazyme's top domains

Analyze Orphazyme engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Orphazyme's top domains

See how Orphazyme keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

orphazyme.com--

See more with Sales Intelligence

Orphazyme top competitors by domain

Top similar sites in January 2026, ranked by their affinity

adienne.comCompany NameAdienneEmployees51 - 200HQSwitzerland, LuganoAnnual revenue$15M - $25MTotal visits915Health > Biotechnology and Pharmaceuticals

Top technologies used by Orphazyme

These are the website technologies, by industry, used by Orphazyme top domains

Payment & Currencies (10)

Cart Functionality

Content Management System (3)

WordPress

Conversion & Analytics (3)

Google Analytics

Advertising (2)

PubMatic

More Technologies

9

See all

News & Signals from Orphazyme

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsOrphazyme Aps sold assets to Zevra Therapeutics, Inc. in the amount of $12.8M on May 1st '22.In May 2022, Zevra, then KemPharm, acquired arimoclomol, an orally-delivered, first-in-class investigational product candidate for the treatment of Niemann-Pick type C disease (“NPC”), from Orphazyme A/S as part of the Company’s long-term vision to evolve into a commercially-driven rare disease therapeutics company.

NewsOrphazyme Aps went public on Sep 1st '20.In September 2020, Orphazyme completed its initial public offering (“IPO”), selling approximately 4 million American Depositary Shares (“ADSs” or “shares”) at $11.00 per share.

NewsOrphazyme Aps sells assets to KemPharm, Inc. in the amount of $12.8M.Per the agreement, KemPharm will acquire all the assets and operations of Orphazyme for $12.8 million in cash.